<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05026177</url>
  </required_header>
  <id_info>
    <org_study_id>PTI-125-06</org_study_id>
    <nct_id>NCT05026177</nct_id>
  </id_info>
  <brief_title>Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease</brief_title>
  <acronym>REFOCUS-ALZ</acronym>
  <official_title>A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cassava Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cassava Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants&#xD;
      with mild-to-moderate Alzheimer's disease (AD) for 76 weeks. Approximately 1083 participants&#xD;
      will be randomized (1:1:1) to receive either placebo, 50 mg tablets of simufilam, or 100 mg&#xD;
      tablets of simufilam, twice daily, for 76 weeks. Clinic visits will occur 4 weeks after the&#xD;
      baseline visit, and then every 12 weeks until the end of the study. The safety of simufilam,&#xD;
      and its efficacy in enhancing cognition and slowing cognitive and functional decline will be&#xD;
      evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to investigate the safety and efficacy of simufilam&#xD;
      (PTI-125) in enhancing cognition and slowing cognitive and functional decline following&#xD;
      76-week, repeat-dose oral administration in participants with mild-to-moderate AD. Secondary&#xD;
      objectives are to assess neuropsychiatric symptoms and to replicate the cerebrospinal fluid&#xD;
      (CSF) biomarker effects observed in the two Phase 2 studies (PTI-125-03 and PTI-125-02) after&#xD;
      76 weeks of simufilam treatment. A third objective is to investigate the effect of simufilam&#xD;
      treatment on plasma biomarkers as well as anatomical correlates of disease progression (brain&#xD;
      volume [hippocampus, ventricles and whole brain]; and amyloid and tau deposition in the&#xD;
      brain). A limited number of research sites will be invited to participate in sub-studies to&#xD;
      assess the impact of simufilam on anatomical and biomarker endpoints, including: change from&#xD;
      baseline in CSF biomarkers (30 subjects/group); brain volume via magnetic resonance imaging&#xD;
      (MRI) (50 subjects/group); and amyloid and tau positron emission tomography (PET) (40 and 50&#xD;
      subjects/group, respectively). Participants in both PET sub-studies will provide plasma for a&#xD;
      biomarker sub-study, and those in the tau PET sub-study will also provide additional plasma&#xD;
      for a pharmacokinetic (PK) exposure response analysis. Changes from baseline for these&#xD;
      imaging and fluid biomarkers represent additional secondary endpoints. The 90 subjects (30&#xD;
      per group) in the CSF sub-study will undergo lumbar puncture during the Screening Period and&#xD;
      again at the Week 76 End-of-Treatment Visit to collect CSF biomarkers.&#xD;
&#xD;
      Safety will be evaluated by adverse event monitoring, vital signs, clinical labs, and the&#xD;
      Columbia Suicide Severity Rating Scale at every visit. All subjects will undergo magnetic&#xD;
      resonance imaging (MRI) during screening to ensure entry criteria are met, however, 150&#xD;
      subjects (50 subjects per treatment group) will also undergo repeat MRI assessments at Weeks&#xD;
      40 and 76 to assess both long-term safety and drug impact on brain volume as noted above.&#xD;
      Electrocardiograms will be conducted on Day 1 and Weeks 4, 40 and 76. A complete physical and&#xD;
      neurological examination will be performed at screening, and brief examinations will be&#xD;
      performed at all other visits. Weight will be measured during the Screening Period, on Study&#xD;
      Day 1 and at all other visits.&#xD;
&#xD;
      An independent Data Safety Monitoring Board (DSMB) will meet periodically to review subject&#xD;
      safety assessments and determine if dosing may continue. A charter will be developed with&#xD;
      specific guidance for the DSMB.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomized treatments will be assigned by subject numbers in a randomly generated numeric sequence. Randomization (1:1:1) will be stratified by low or high Mini-Mental State Exam (MMSE; 16-20 and 21-27).&#xD;
The randomization code will not be revealed to study subjects, Investigators, clinical staff, study monitors or the Sponsor until all subjects have completed therapy and the database has been finalized and locked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the ADAS-Cog12, a psychometrician-administered battery comprised of several cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech. Scores range from 0 (best) to 80 (worst).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the ADCS-ADL, a 23-item study partner questionnaire that covers both basic activities of daily living (ADL) and more complex ADL or instrumental ADL. Scores range from 0 to 78, with a lower score indicating greater severity of functional loss.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the integrated Alzheimer's Disease Rating Scale (iADRS)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the iADRS, where scores range from 0 to 146 with lower scores indicating worse performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Neuropsychiatric Inventory (NPI)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the NPI, a 12-item study partner interview, which records the frequency and severity of common neuropsychiatric symptoms in dementia, as well as the level of study partner distress due to these neuropsychiatric problems. Scores range from 0 to 144, with higher scores indicating more frequent and severe symptoms, and greater levels of partner distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the MMSE</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the MMSE, a set of standardized questions covering several target areas: orientation, registration, attention and calculation, short-term verbal recall, naming, repetition, 3-step command, reading, writing, and visuospatial cognitive assessment. Lower sores indicate more severe impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Clinical Dementia Rating Sum of Boxes (CDR-SB)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the CDR-SB, which characterizes 6 domains of cognitive and functional performance applicable to AD and related dementias: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Higher scores indicate more severe impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Zarit Burden Interview (ZBI)</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>The change from baseline to Week 76 in the ZBI, a 22-item study partner questionnaire designed to assess the stress or burden experienced by caregivers of people with dementia, with a higher score indicating greater stress or burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in CSF neurogranin, neurofilament light chain, total tau, phospho-tau181 (P-tau181), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), and Aβ42</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>Changes from baseline in CSF biomarkers of AD pathology, neurodegeneration, and neuroinflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in brain volume via MRI</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>Changes from baseline in hippocampus, ventricles, and whole brain volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in amyloid and tau PET</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>Changes from baseline in amyloid and tau deposition in the brain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in plasma biomarkers P-tau181 and neurofilament light chain</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>Change from baseline in plasma biomarkers of AD pathology and neurodegeneration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma biomarker SavaDx</measure>
    <time_frame>Baseline (Study Day 1) to Week 76</time_frame>
    <description>SavaDx is a novel plasma biomarker</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1083</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 76 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simufilam 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simufilam 50 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simufilam 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 76 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simufilam</intervention_name>
    <description>Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 76 weeks at a dose of 50 mg or 100 mg.</description>
    <arm_group_label>Simufilam 100 mg</arm_group_label>
    <arm_group_label>Simufilam 50 mg</arm_group_label>
    <other_name>PTI-125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo given b.i.d. for 76 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Meets National Institute on Aging and Alzheimer's Association Research Framework&#xD;
             criteria for individuals in clinical Stage 4 or 5 of the Alzheimer's continuum.&#xD;
&#xD;
          2. Evidence for AD pathophysiology, confirmed prior to or during screening&#xD;
&#xD;
          3. MMSE score ≥ 16 and ≤ 27 at screening.&#xD;
&#xD;
          4. Clinical Dementia Rating - Global Score must be 0.5, 1 or 2.&#xD;
&#xD;
          5. If receiving background AD medications, the dosing regimen must be stable for at least&#xD;
             12 weeks prior to randomization.&#xD;
&#xD;
          6. The subject has been a non-smoker for at least 3 years.&#xD;
&#xD;
          7. Availability of a study partner&#xD;
&#xD;
          8. Individuals who have participated in a clinical study with an investigational drug&#xD;
             targeting the underlying AD process may be permitted to participate in this study.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. A neurologic condition other than AD that significantly contributes to the subject's&#xD;
             dementia.&#xD;
&#xD;
          2. Any current primary psychiatric diagnosis other than AD if it is likely to confound&#xD;
             cognitive assessment or ability to comply with study procedures&#xD;
&#xD;
          3. Geriatric Depression Scale (15-item) score &gt; 8&#xD;
&#xD;
          4. Suicidal ideation during the past 3 months or suicidal behavior during the past 12&#xD;
             months&#xD;
&#xD;
          5. Alcohol or substance use disorder within 2 years of screening&#xD;
&#xD;
          6. MRI presence of cerebral vascular or other significant pathology&#xD;
&#xD;
          7. History of transient ischemic attack or stroke within 12 months of screening&#xD;
&#xD;
          8. Seizure within 12 months of screening.&#xD;
&#xD;
          9. Severe head trauma or head trauma considered likely to be contributing to the&#xD;
             subject's cognitive impairment.&#xD;
&#xD;
         10. Sleep apnea that is considered likely to be contributing to the subject's cognitive&#xD;
             impairment.&#xD;
&#xD;
         11. Insufficiently controlled diabetes mellitus or hypertension&#xD;
&#xD;
         12. Body mass index &lt; 18.5 or &gt; 35.0.&#xD;
&#xD;
         13. History or diagnosis of clinically significant cardiac disease&#xD;
&#xD;
         14. Prescribed aducanumab.&#xD;
&#xD;
         15. COVID-19 infection within 3 months of screening. If no history of a prior COVID-19&#xD;
             infection, subject must be fully vaccinated for COVID-19 at least 2 weeks prior to&#xD;
             randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>87 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Kupiec, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cassava Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>737-910-1045</phone>
    <email>ClinicalTrials.gov@cassavasciences.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Po-Heng Tsai, MD</last_name>
      <phone>602-839-0588</phone>
      <email>Po-Heng.Tsai@bannerhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Zigler</last_name>
      <phone>602-839-0588</phone>
      <email>Lisa.Zigler@bannerhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Po-Heng Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Neuroscience Research, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yareli Pena</last_name>
      <phone>480-210-8723</phone>
      <email>yareli@centerforneurologyandspine.com</email>
    </contact>
    <contact_backup>
      <last_name>Calvin Truong</last_name>
      <phone>480-210-8723</phone>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Gitt, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Endpoints</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan Block, MD</last_name>
      <phone>480-566-9090</phone>
      <email>clinicalresearch@imagingendpoints.com</email>
    </contact>
    <contact_backup>
      <last_name>Crystal Brown</last_name>
      <phone>480-566-9090</phone>
      <email>clbrown@clinicalendpoints.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allan Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Goldfarb, MD</last_name>
      <phone>623-832-6530</phone>
      <email>danielle.goldfarb@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Danielle Goldfarb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Alzheimer's Institute - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Sipes</last_name>
      <phone>520-694-4217</phone>
      <email>joshua.sipes@bannerhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Schafer</last_name>
      <phone>619-322-6040</phone>
      <email>kimberly.schafer@bannerhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Allan Anderson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North County Neurology Associates</name>
      <address>
        <city>Carlsbad</city>
        <state>California</state>
        <zip>92011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estela Soto</last_name>
      <phone>760-732-0557</phone>
      <phone_ext>2123</phone_ext>
      <email>ESTELA.SOTO@NEUROCENTER.COM</email>
    </contact>
    <investigator>
      <last_name>Benjamin Frishberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro-Pain Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Perminder Bhatia, MD</last_name>
      <phone>718-317-5522</phone>
      <email>BHATIA@NEUROPAIN.COM</email>
    </contact>
    <contact_backup>
      <last_name>Janeen Tugas</last_name>
      <email>janeen@neuropain.com</email>
    </contact_backup>
    <investigator>
      <last_name>Perminder Bhatia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Center of North Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johnson Moon, MD</last_name>
      <phone>714-879-7200</phone>
      <email>johnson.l.moon@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Chavez</last_name>
      <phone>714-879-7200</phone>
      <email>schavez@neurologyoc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Johnson Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Research Insitute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nelson Owyoung, MD</last_name>
      <phone>323-749-6361</phone>
      <email>owyoung.caresinst@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ghassan Al-Jazayrly</last_name>
      <phone>323-660-6200</phone>
      <email>pi@caresinst.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nelson Owyoung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shankle Clinic and Hoag Memorial Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selia Shamirian</last_name>
      <phone>949-764-8190</phone>
      <email>Selia.Shamirian@hoag.org</email>
    </contact>
    <investigator>
      <last_name>William Shankle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Research Network, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Thein, PhD</last_name>
      <phone>619-294-4302</phone>
      <email>sthein@ergclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Alison Walton</last_name>
      <phone>619-294-4302</phone>
      <email>Awalton@ergclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Thein, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco: Memory and Aging Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Nuvance Health Medical Practice CT, Inc. - Associated Neurologists, PC</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dawn Marie Morsey</last_name>
      <phone>203-739-6019</phone>
      <email>dawnmarie.morsey@nuvancehealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ki Health Partners, LLC</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valerija Misev</last_name>
      <phone>203-914-1903</phone>
      <email>valerija@neinh.com</email>
    </contact>
    <contact_backup>
      <last_name>Peter McAllister, MD</last_name>
      <phone>203-914-1903</phone>
      <email>peter@neinh.com</email>
    </contact_backup>
    <investigator>
      <last_name>Peter McAllister, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>JEM Research Institute</name>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <zip>33462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Goldstein, MD</last_name>
      <phone>561-968-2933</phone>
      <email>mgoldstein@jemri.net</email>
    </contact>
    <contact_backup>
      <last_name>Jetliza Lesmes</last_name>
      <phone>561-968-2933</phone>
      <email>jlesmes@jemri.net</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Goldstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkinson's Disease and Movement Disorders Center of Boca Raton</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Carvalho</last_name>
      <phone>561-392-1818</phone>
      <phone_ext>2</phone_ext>
      <email>mcarvalho@ParkinsonsCenter.org</email>
    </contact>
    <contact_backup>
      <last_name>Lisbeth Pennente</last_name>
      <phone>561-392-1818</phone>
      <phone_ext>2</phone_ext>
      <email>lcarvajal@ParkinsonsCenter.org</email>
    </contact_backup>
    <investigator>
      <last_name>Stuart Isaacson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Brandon, LLC</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maylin Barrios</last_name>
      <email>mbarrios@crofb.com</email>
    </contact>
    <investigator>
      <last_name>German Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research Inc</name>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <zip>33445</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paayal Patel, MD</last_name>
      <phone>561-374-8461</phone>
      <email>ppatel@ergclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Blasi</last_name>
      <phone>561-374-8461</phone>
      <email>jblasi@ergclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paayal Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evelio Sosa, MD</last_name>
      <phone>305-825-6588</phone>
      <email>esosa@indagoresearch.org</email>
    </contact>
    <contact_backup>
      <last_name>Yisel Hernandez</last_name>
      <phone>305-825-6588</phone>
      <email>yhernandez@indagoresearch.org</email>
    </contact_backup>
    <investigator>
      <last_name>Evelio Sosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mind Institute at Miami Jewish Health</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33137</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Gomez</last_name>
      <phone>305-751-8626</phone>
      <email>agomez@miamijewishhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Isesalaya</last_name>
      <phone>305-751-8626</phone>
      <email>misesalaya@miamijewishhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Agronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brainstorm Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brad Herskowitz</last_name>
      <phone>305-701-2091</phone>
      <email>bherskowitz@brainstormresearch.net</email>
    </contact>
    <contact_backup>
      <last_name>Savannah Rodriguez</last_name>
      <phone>305-701-2091</phone>
      <email>srodriguez@brainstormresearch.net</email>
    </contact_backup>
    <investigator>
      <last_name>Brad Herskowitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Synergy Clinical Research</name>
      <address>
        <city>Okeechobee</city>
        <state>Florida</state>
        <zip>34972</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Winberg</last_name>
      <phone>786-863-3325</phone>
      <email>mwinberg@healthsynergyclinicalresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Uhl</last_name>
      <phone>786-863-3325</phone>
      <email>muhl@healthsynergyclinicalresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mohammad Asim Nisar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research Group of Central Florida</name>
      <address>
        <city>Orange City</city>
        <state>Florida</state>
        <zip>32763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Clinical Neuroscience Solutions, Inc. dba CNS Healthcare</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Molpus, MD</last_name>
      <phone>386-775-7627</phone>
      <email>rmolpus@cnshealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Robert Molpus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quantum Laboratories</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Herr</last_name>
      <phone>954-933-2324</phone>
      <email>karen.herr@quantum-lab.com</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Jaucian</last_name>
      <phone>954-933-2324</phone>
      <email>ellenjaucian@quantum-lab.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jose De La Gandara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intercoastal Medical Group - Sarasota</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Wilson</last_name>
      <phone>941-404-4390</phone>
      <email>JeWilson@intercoastalmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Robin Pannell</last_name>
      <phone>941-404-4277</phone>
      <email>rpannell@intercoastalmedical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mauricio Concha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research &amp; Treatment Center</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lipofsky, MD</last_name>
      <phone>772-675-0000</phone>
      <email>jlipofsky@researchalz.com</email>
    </contact>
    <contact_backup>
      <last_name>Kaitlyn Knowlton</last_name>
      <phone>772-675-0000</phone>
      <email>kknowlton@researchalz.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Watson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brain Matters Research Inc</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34997</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paayal Patel, MD</last_name>
      <phone>561-374-8461</phone>
      <email>ppatel@ergclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Gina Collazo</last_name>
      <phone>772-223-7880</phone>
      <email>GCOLLAZO@ERGCLINICAL.COM</email>
    </contact_backup>
    <investigator>
      <last_name>Paayal Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USF Health - Byrd Alzheimer's Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Breanna Davis</last_name>
      <phone>813-974-5296</phone>
      <email>breannadavis@usf.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Colombo</last_name>
      <phone>813-974-9383</phone>
      <email>colombok@usf.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amanda Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alzheimer's Research &amp; Treatment Center</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sydney Werner, MD</last_name>
      <phone>561-209-2400</phone>
      <email>swerner@researchalz.com</email>
    </contact>
    <contact_backup>
      <last_name>Venessa Ranney</last_name>
    </contact_backup>
    <investigator>
      <last_name>David Watson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Conquest Research</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa O'Neill</last_name>
      <phone>407-848-3845</phone>
      <email>melissa.oneill@conquestresearch.com</email>
    </contact>
    <investigator>
      <last_name>Rekha Gandhi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Memory Center, PC</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Liss, MD</last_name>
      <phone>706-653-8455</phone>
      <email>jliss@lissmd.com</email>
    </contact>
    <contact_backup>
      <last_name>Piper Gilley</last_name>
      <phone>706-653-8455</phone>
      <email>research7@stork.md</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Liss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accel Research Sites - NeuroStudies</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Hilliard</last_name>
      <phone>404-475-0552</phone>
      <email>ahilliard@accelclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Cavin</last_name>
      <phone>404-475-0552</phone>
      <email>jcavin@accelclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marshall Nash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Potocki</last_name>
      <phone>773-275-3513</phone>
      <email>kpotocki@greatlakesclinicaltrials.com</email>
    </contact>
    <contact_backup>
      <last_name>Jiyul Kim</last_name>
      <phone>773-275-3513</phone>
      <email>jkim@greatlakesclinicaltrials.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Aurora Health</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Streeter</last_name>
      <phone>847-723-8927</phone>
      <email>Samuel.Streeter@aah.org</email>
    </contact>
    <investigator>
      <last_name>Darren Gitelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Sanders-Brown Center on Aging</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keisha Jones</last_name>
      <phone>859-323-1331</phone>
      <email>kcl.jones@uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Vires</last_name>
      <phone>859-257-6507</phone>
      <email>kbvire2@uky.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Jicha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ActivMed Practices &amp; Research, LLC</name>
      <address>
        <city>Methuen</city>
        <state>Massachusetts</state>
        <zip>01844</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfaurys Rosario</last_name>
      <phone>978-655-7155</phone>
      <email>alfaurys.rosario@activmedresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Madeline Puracchio</last_name>
      <phone>978-655-7155</phone>
      <email>madeline.puracchio@activmedresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael McCartney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Center for Memory</name>
      <address>
        <city>Newton</city>
        <state>Massachusetts</state>
        <zip>02459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Solomon, PhD</last_name>
      <phone>617-699-6927</phone>
      <email>paul@bostonmemory.com</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Vassey</last_name>
      <phone>617-699-6927</phone>
      <email>elizabeth@bostonmemory.com</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Solomon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Office of Donald S. Marks, M.D., P.C.</name>
      <address>
        <city>Plymouth</city>
        <state>Massachusetts</state>
        <zip>02360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Kearney</last_name>
      <phone>508-746-5060</phone>
      <email>elainek@dsmmdpc.com</email>
    </contact>
    <contact_backup>
      <last_name>Erin Kearney</last_name>
      <phone>508-746-5060</phone>
      <email>erink@dsmmdpc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Donald Marks, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedVadis Research</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Counihan</last_name>
      <phone>617-744-1310</phone>
      <email>dcounihan@medvadis.com</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Landyn</last_name>
      <phone>617-744-1310</phone>
      <email>regulatory@medvadis.com</email>
    </contact_backup>
    <investigator>
      <last_name>David DiBenedetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Global Medical Institutes, LLC</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee White</last_name>
      <phone>609-921-3555</phone>
      <email>kwhite@gminstitutes.com</email>
    </contact>
    <investigator>
      <last_name>James Wolberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cognitive and Research Center of New Jersey (CRCNJ)</name>
      <address>
        <city>Springfield</city>
        <state>New Jersey</state>
        <zip>07081</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Tabman</last_name>
      <phone>973-850-4622</phone>
      <email>jtabman@thecrcnj.com</email>
    </contact>
    <contact_backup>
      <last_name>Chelsea Negro</last_name>
      <phone>973-850-4622</phone>
      <email>cnigro@thecrcnj.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michelle Papka, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Memory Research Institute of NJ</name>
      <address>
        <city>Toms River</city>
        <state>New Jersey</state>
        <zip>08755</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Storey</last_name>
      <phone>732-341-9500</phone>
      <email>estorey@amrinj.com</email>
    </contact>
    <investigator>
      <last_name>Sanjiv Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Specialists of Monmouth County</name>
      <address>
        <city>West Long Branch</city>
        <state>New Jersey</state>
        <zip>07764</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noah Gilson, MD</last_name>
      <phone>732-935-1850</phone>
      <email>ngmdresearch@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Avraham Tuvy</last_name>
      <phone>732-935-1850</phone>
      <email>avtuvy@neurologyspecialists.org</email>
    </contact_backup>
    <investigator>
      <last_name>Noah Gilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hart, MD</last_name>
      <phone>518-262-0800</phone>
      <email>hartd3@amc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katlynn Patterson</last_name>
      <phone>518-264-6192</phone>
      <email>patterk3@amc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David Hart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurological Associates of Albany</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Holub, MD</last_name>
      <phone>518-426-0575</phone>
      <email>rholub@naaresearch.com</email>
    </contact>
    <contact_backup>
      <last_name>Dawn Kalbfliesh</last_name>
      <phone>518-426-0575</phone>
      <email>dkalbfliesh@naaresearch.com</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Holub, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michael I Weintraub, MD, PC</name>
      <address>
        <city>Briarcliff Manor</city>
        <state>New York</state>
        <zip>10510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Integrative Clinical Trials</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Yuryev, DO</last_name>
      <phone>718-444-7774</phone>
      <email>michael.yuryev@iclinicaltrials.net</email>
    </contact>
    <contact_backup>
      <last_name>Lyudmila Grishina</last_name>
      <phone>718-444-7774</phone>
      <email>Lyudmila.grishina@iclinicaltrials.net</email>
    </contact_backup>
    <investigator>
      <last_name>Inna Yuryev-Golger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPRI Clinical Trials Brooklyn</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatyana Tsiporin</last_name>
      <phone>646-747-4060</phone>
      <email>ttsiporin@spristudy.com</email>
    </contact>
    <contact_backup>
      <last_name>Nick Vatakis, MD</last_name>
      <phone>718-616-2230</phone>
      <email>nvatakis@spristudy.com</email>
    </contact_backup>
    <investigator>
      <last_name>Nick Vatakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Velocity Clinical Research, Formerly Clarity Clinical Research</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Cupelo, MD</last_name>
      <phone>315-760-5905</phone>
      <email>syracuse@velocityclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Kristen Stebbins</last_name>
      <phone>315-283-3435</phone>
      <email>kstebbins@velocityclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Cupelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Richmond Behavioral Associates</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10312</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark DiBuono, MD</last_name>
      <phone>760-631-3000</phone>
      <email>mdibuono@ergclinical.com</email>
    </contact>
    <contact_backup>
      <last_name>Priya Selvarajah</last_name>
      <phone>718-317-5526</phone>
      <phone_ext>1311</phone_ext>
      <email>pselvarajah@ergclinical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mark DiBuono, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Accellacare Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell Isaac, MD</last_name>
      <phone>336-768-6347</phone>
      <email>misaac@wakehealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Annette Wood</last_name>
      <phone>336-768-8062</phone>
      <email>Annette.Wood@accellacare.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell Isaac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Douglas Scharre, MD</last_name>
      <phone>614-293-4969</phone>
      <email>doug.scharre@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jenny Icenhour</last_name>
      <phone>614-293-6882</phone>
      <email>jennifer.icenhour@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Douglas Scharre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Diagnostics</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel Vandersluis, MD</last_name>
      <phone>937-224-8200</phone>
      <email>research@dcndinc.com</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Current</last_name>
      <phone>937-224-8200</phone>
      <email>ellen.current@neurologydiagnostics.com</email>
    </contact_backup>
    <investigator>
      <last_name>Joel Vandersluis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neuro-Behavioral Clinical Research (NBCR)</name>
      <address>
        <city>North Canton</city>
        <state>Ohio</state>
        <zip>44720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shishuka Malhotra, MD</last_name>
      <phone>330-493-1118</phone>
      <email>smalhotra@nb-cr.com</email>
    </contact>
    <contact_backup>
      <last_name>Megan Smith</last_name>
      <phone>330-493-1118</phone>
      <email>msmith@nb-cr.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shishuka Malhotra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center for Cognitive Health - Portland</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ericka Eyton</last_name>
      <phone>503-207-2066</phone>
      <email>ericka@centerforcognitivehealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Michael Mega, MD</last_name>
      <phone>503-207-2066</phone>
      <email>michael@centerforcognitivehealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Mega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marvin Kalafer, MD</last_name>
      <phone>215-884-1700</phone>
      <email>drkalafer@theclinicaltrialcenter.com</email>
    </contact>
    <contact_backup>
      <last_name>Alketa Dobi</last_name>
      <phone>215-884-1700</phone>
      <email>alketa@theclinicaltrialcenter.com</email>
    </contact_backup>
    <investigator>
      <last_name>Marvin Kalafer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keystone Clinical Studies, LLC</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherian Verghese, MD</last_name>
      <phone>610-277-8073</phone>
      <phone_ext>203</phone_ext>
      <email>cherian.verghese@keystoneclinicalstudies.com</email>
    </contact>
    <contact_backup>
      <last_name>Rachel Glick</last_name>
      <phone>610-277-8073</phone>
      <phone_ext>203</phone_ext>
      <email>rachel.glick@keystoneclinicalstudies.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cherian Verghese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KCA Neurology, PLLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gretchen Campbell, MD</last_name>
      <phone>615-550-1800</phone>
      <email>gcampbell@kcadocs.com</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Cowan</last_name>
      <phone>931-434-0959</phone>
      <email>jcowan@kcadocs.com</email>
    </contact_backup>
    <investigator>
      <last_name>Gretchen Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Neurology Consultants of Dallas, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Christina Howell</last_name>
      <phone>214-750-9977</phone>
      <phone_ext>293</phone_ext>
      <email>jchowell@neurologydallas.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Zutter</last_name>
      <phone>214-750-9977</phone>
      <phone_ext>293</phone_ext>
      <email>lzutter@neurologydallas.com</email>
    </contact_backup>
    <investigator>
      <last_name>Duc Tran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Memory Clinic - Bennington</name>
      <address>
        <city>Bennington</city>
        <state>Vermont</state>
        <zip>05201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guy deBros</last_name>
      <phone>802-447-1409</phone>
      <email>guy@memorydoc.org</email>
    </contact>
    <contact_backup>
      <last_name>Cynthia Murphy, PsyD</last_name>
      <phone>802-447-1409</phone>
      <email>cynthia@memorydoc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Murphy, PsyD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Hall</last_name>
      <phone>425-453-0404</phone>
      <email>rhall@nwcrc.net</email>
    </contact>
    <contact_backup>
      <last_name>Arifulla Khan</last_name>
      <phone>425-453-0404</phone>
      <email>akhan@nwcrc.net</email>
    </contact_backup>
    <investigator>
      <last_name>Arifulla Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malgorzata Franczak, MD</last_name>
      <phone>414-955-0657</phone>
      <email>mfranczak@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Peter Kraegel</last_name>
      <phone>414-955-0657</phone>
      <email>pkraegel@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Malgorzata Franczak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OCT Research ULC DBA Okanagan Clinical Trials</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 2Z9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene Okorie, MD</last_name>
      <phone>250-862-8141</phone>
      <email>drokorie@oktrials.ca</email>
    </contact>
    <contact_backup>
      <last_name>Emily Eisner, MD</last_name>
      <phone>250-862-8141</phone>
      <email>emily@oktrials.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Eugene Okorie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Djavad Mowafaghian Centre for Brain Health</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Assaly</last_name>
      <phone>604-822-1782</phone>
      <email>Michele.Assaly@vch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Ellen Kim</last_name>
      <phone>604-827-2015</phone>
      <email>Ellen.Kim@vch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Robin Hsiung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Dr-Georges-L.-Dumont (CHUDGLD)</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 2Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludivine Witkowski, MD</last_name>
      <phone>506-869-7211</phone>
      <email>ludivine.witkowski@vitalitenb.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kendra Cooling</last_name>
      <phone>506 869 7391</phone>
      <email>kendra.cooling@vitalitenb.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Ludivine Witkowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research - Halifax</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3S 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Veinott</last_name>
      <phone>902-431-4433</phone>
      <email>brittany.veinott@truenorthcr.com</email>
    </contact>
    <investigator>
      <last_name>Rodney Brittain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>True North Clinical Research - New Minas</name>
      <address>
        <city>New Minas</city>
        <state>Nova Scotia</state>
        <zip>B4N 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Walters-Findlay</last_name>
      <phone>902-365-3065</phone>
      <email>info@truenorthcr.com</email>
    </contact>
    <investigator>
      <last_name>Robert Mullan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Centre for Memory and Aging</name>
      <address>
        <city>Toronto</city>
        <state>Ontariop</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Marotta, MD</last_name>
      <phone>416-645-2929</phone>
      <email>marottaresearchmemory@LMCmanna.com</email>
    </contact>
    <contact_backup>
      <last_name>Recruitment Team Lead</last_name>
      <email>research@LMCmanna.com</email>
    </contact_backup>
    <investigator>
      <last_name>Giovanni Marotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Health Care London</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 0A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Silveira</last_name>
      <phone>519-646-6100</phone>
      <phone_ext>42367</phone_ext>
      <email>Carolina.Silveira@sjhc.london.on.ca</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Borron</last_name>
      <phone>519-646-6100</phone>
      <phone_ext>45055</phone_ext>
      <email>Kathy.Borron@sjhc.london.on.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen Pasternak, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Memory Clinic</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Z 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Bergeron, MD</last_name>
      <phone>613-702-1000</phone>
      <phone_ext>415</phone_ext>
      <email>rbergeron@cliniquememoire.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Ross</last_name>
      <phone>613-702-1000</phone>
      <phone_ext>465</phone_ext>
      <email>jross@thememoryclinic.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Bergeron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kawartha Centre - Redefining Healthy Aging</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9H2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra Trudell</last_name>
      <phone>705-749-3906</phone>
      <phone_ext>211</phone_ext>
      <email>sandra@kawarthacentre.com</email>
    </contact>
    <contact_backup>
      <last_name>Krista Gillis</last_name>
      <phone>705-749-3906</phone>
      <email>krista@kawarthacentre.com</email>
    </contact_backup>
    <investigator>
      <last_name>Katie Krause, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto Memory Program</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3B 2S7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Cohen</last_name>
      <phone>416-386-9761</phone>
      <email>icohen@memorydisorders.ca</email>
    </contact>
    <contact_backup>
      <last_name>Dale Commerford</last_name>
      <phone>416-386-9761</phone>
      <email>dcommerford@memorydisorders.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Recherches Neuro-Hippocampe Inc.</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8T 8J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Bergeron, MD</last_name>
      <phone>819-510-1000</phone>
      <email>rbergeron@cliniquememoire.ca</email>
    </contact>
    <contact_backup>
      <last_name>Bianca Régimbald</last_name>
      <phone>819-510-1000</phone>
      <phone_ext>235</phone_ext>
      <email>bregimbald@cliniquememoire.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Bergeron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Chilgok Hospital</name>
      <address>
        <city>Daegu</city>
        <state>North Gyeongsang Province</state>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jung-Eun Kim</last_name>
      <phone>82-10-5578-2939</phone>
      <email>jungeun128@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Hae-Jeong Kang</last_name>
      <phone>82-10-7917-5753</phone>
      <email>gowjddl0302@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ho-Won Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Cruz Behavioral PSC</name>
      <address>
        <city>Bayamón</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ivelisse Rojas</last_name>
      <phone>787-798-4592</phone>
      <phone_ext>237</phone_ext>
      <email>irojas@santacruzbehavioral.com</email>
    </contact>
    <contact_backup>
      <last_name>Karen Pujals</last_name>
      <phone>787-798-4592</phone>
      <phone_ext>237</phone_ext>
      <email>kpujals@santacruzbehavioral.com</email>
    </contact_backup>
    <investigator>
      <last_name>William Julio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspira Clinical Research</name>
      <address>
        <city>San Juan</city>
        <zip>00918</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yvette Cruz-Pagan, MD</last_name>
      <phone>787-753-9515</phone>
      <phone_ext>296</phone_ext>
      <email>ycruz@inspirapr.com</email>
    </contact>
    <contact_backup>
      <last_name>Milagros Alamo-Febres</last_name>
      <phone>787-753-9515</phone>
      <email>estudio@inspirapr.com</email>
    </contact_backup>
    <investigator>
      <last_name>Yvette Cruz-Pagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Diaz Hernandez Md Research, Inc.</name>
      <address>
        <city>San Juan</city>
        <zip>00926</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisol Mubarak-Perdomo, MD</last_name>
      <phone>787-523-9808</phone>
      <email>mmubarak@bdhresearch.com</email>
    </contact>
    <investigator>
      <last_name>Marisol Mubarak-Perdomo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto De Neurologia Dra. Ivonne Fraga</name>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Sanchez-Garcia, PhD</last_name>
      <phone>787-209-2868</phone>
      <email>nataliesanchez.phd@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Martha Escobar</last_name>
      <email>mescobarccrp@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ivonne Fraga-Berrios, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Korea, Republic of</country>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>August 9, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2021</study_first_posted>
  <last_update_submitted>September 28, 2022</last_update_submitted>
  <last_update_submitted_qc>September 28, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

